Caroline Gertrud Bergner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Caroline Gertrud Bergner has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Wolfgang Köhler
Department of Neurology University Medical Center Leipzig Germany
5 shared publications - Julia Lier
Department of Neurology University Medical Center Leipzig Germany
4 shared publications - Ayelet Zerem
Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel
3 shared publications - Caroline Sevin
INSERM U 1127, CNRS UMR 7225, Sorbonne Université, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau, ICM, France
3 shared publications - Fanny Mochel
Reference Center for Adult Neurometabolic Diseases and Leukodystrophies, Department of Medical Genetics of APHP, Sorbonne University, Paris Brain Institute (ICM), La Pitié-Salpêtrière University Hospital
3 shared publications - Lisa Schäfer
Department of Neurology, Leipzig University Medical Center, Germany
3 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wiley in Brain Pathology
Spatial evolution of microglial phenotypes and iron accumulation in CSF1R ‐associated leukoencephalopathy
Colony‐stimulating factor 1 receptor (CSF1R)‐associated leukoencephalopathy (CSF1R‐LE) is a fatal genetic white matter disease, whose onset is most commonly in mid‐age adulthood, and is characterized by rapid neurological decline and premature death within a few years after disease onset. CSF1R is exclusively expressed by microglia in the parenchyma of the adult central nervous system, thus defining CSF1R‐LE as a paradigmatic primary microgliopathy. However, the cellular alterations that drive the sudden onset and rapid progression of the disease remain largely unknown. Therefore, the investigation of microglia phenotypes in human histopathological tissue, particularly considering the spatial evolution of the pathology, can provide crucial insights into the disease‐causing mechanisms. In this study, we (immuno‐) histochemically characterized myeloid cell pathology in relation to the extent of damage to the axon‐myelin unit in five autopsy cases of CSF1R‐LE. A particular focus was on the relationship between microglia phenotypes and the pronounced iron accumulation observed in this disease. Our findings provide evidence that the early loss of homeostatic microglia and inflammatory activation of remaining myeloid cells are key components of areas with mild tissue pathology. Furthermore, we demonstrate a marked and progressive accumulation of iron within myeloid cells paralleling increasing white matter damage. This process is associated with ongoing myelin degeneration and occurs in the apparent absence of efficient remyelination. In summary, our study reveals stage‐specific myeloid cell pathology in CSF1R‐LE and highlights a specific spatial heterogeneity that should be considered when studying this disease. Moreover, our findings suggest that cellular iron accumulation may not only contribute to disease progression but may also represent a promising and clinically accessible biomarker for CSF1R‐LE.
- 11 November 2026
- Published by Wiley in Brain Pathology
Open AccessSpatial evolution of microglial phenotypes and iron accumulation in CSF1R ‐associated leukoencephalopathy
Colony‐stimulating factor 1 receptor (CSF1R)‐associated leukoencephalopathy (CSF1R‐LE) is a fatal genetic white matter disease, whose onset is most commonly in mid‐age adulthood, and is characterized by rapid neurological decline and premature death within a few years after disease onset. CSF1R is exclusively expressed by microglia in the parenchyma of the adult central nervous system, thus defining CSF1R‐LE as a paradigmatic primary microgliopathy. However, the cellular alterations that drive the sudden onset and rapid progression of the disease remain largely unknown. Therefore, the investigation of microglia phenotypes in human histopathological tissue, particularly considering the spatial evolution of the pathology, can provide crucial insights into the disease‐causing mechanisms. In this study, we (immuno‐) histochemically characterized myeloid cell pathology in relation to the extent of damage to the axon‐myelin unit in five autopsy cases of CSF1R‐LE. A particular focus was on the relationship between microglia phenotypes and the pronounced iron accumulation observed in this disease. Our findings provide evidence that the early loss of homeostatic microglia and inflammatory activation of remaining myeloid cells are key components of areas with mild tissue pathology. Furthermore, we demonstrate a marked and progressive accumulation of iron within myeloid cells paralleling increasing white matter damage. This process is associated with ongoing myelin degeneration and occurs in the apparent absence of efficient remyelination. In summary, our study reveals stage‐specific myeloid cell pathology in CSF1R‐LE and highlights a specific spatial heterogeneity that should be considered when studying this disease. Moreover, our findings suggest that cellular iron accumulation may not only contribute to disease progression but may also represent a promising and clinically accessible biomarker for CSF1R‐LE.
- 8 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (5)
Analysis of Interindividual Lesion Progression Variability in Adult Cerebral Adrenoleukodystrophy
- 8 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (5)
Analysis of Interindividual Lesion Progression Variability in Adult Cerebral Adrenoleukodystrophy
- Open Access
- 19 March 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (2) , e70176
Natural History of Clinical Phenotypes and Their Biochemical Correlates in Adult X‐Linked Adrenoleukodystrophy
X‐linked adrenoleukodystrophy (X‐ALD) is a rare monogenic disorder characterized by marked variability in clinical presentation, age at onset, and disease progression. A deeper understanding of its natural history and the relationship between biochemical markers and clinical phenotypes is essential for improving disease monitoring, patient counseling, and optimizing clinical trial design. In particular, the predictive value of very long‐chain fatty acids (VLCFA) for clinical phenotypes has recently garnered increased attention. In this longitudinal, mixed prospective/retrospective, single‐center study, we analyzed clinical and biochemical data from 364 patients with X‐ALD (255 males). Parameters included clinical scores (EDSS, AACS), age at symptom onset, and disease manifestations, which were correlated with individual VLCFA levels. Patients with adrenal insufficiency (AI) exhibited significantly elevated VLCFA concentrations. Higher C26:0 levels were associated with faster progression (measured by EDSS); however, effect sizes were small and inter‐individual variability considerable. Although initial symptom severity was comparable between sexes, males presented earlier and progressed faster. Among patients seen in early clinical stages (EDSS ≤ 4.5), disease progression rates were higher (males: 0.34 ± 0.77; females: 0.11 ± 0.11) than in those presenting at more advanced stages (EDSS > 4.5; males: 0.23 ± 0.33; females: 0.09 ± 0.10). We provide comprehensive data on the prevalence of disease manifestations and the natural course of X‐ALD in a large adult cohort. The observed association between elevated VLCFA levels and adrenal insufficiency should be considered in future clinical monitoring and trial design. However, due to the small effect sizes and variability, VLCFA levels offer limited prognostic utility for individual patients.
- 19 March 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (2) , e70176
Open AccessNatural History of Clinical Phenotypes and Their Biochemical Correlates in Adult X‐Linked Adrenoleukodystrophy
X‐linked adrenoleukodystrophy (X‐ALD) is a rare monogenic disorder characterized by marked variability in clinical presentation, age at onset, and disease progression. A deeper understanding of its natural history and the relationship between biochemical markers and clinical phenotypes is essential for improving disease monitoring, patient counseling, and optimizing clinical trial design. In particular, the predictive value of very long‐chain fatty acids (VLCFA) for clinical phenotypes has recently garnered increased attention. In this longitudinal, mixed prospective/retrospective, single‐center study, we analyzed clinical and biochemical data from 364 patients with X‐ALD (255 males). Parameters included clinical scores (EDSS, AACS), age at symptom onset, and disease manifestations, which were correlated with individual VLCFA levels. Patients with adrenal insufficiency (AI) exhibited significantly elevated VLCFA concentrations. Higher C26:0 levels were associated with faster progression (measured by EDSS); however, effect sizes were small and inter‐individual variability considerable. Although initial symptom severity was comparable between sexes, males presented earlier and progressed faster. Among patients seen in early clinical stages (EDSS ≤ 4.5), disease progression rates were higher (males: 0.34 ± 0.77; females: 0.11 ± 0.11) than in those presenting at more advanced stages (EDSS > 4.5; males: 0.23 ± 0.33; females: 0.09 ± 0.10). We provide comprehensive data on the prevalence of disease manifestations and the natural course of X‐ALD in a large adult cohort. The observed association between elevated VLCFA levels and adrenal insufficiency should be considered in future clinical monitoring and trial design. However, due to the small effect sizes and variability, VLCFA levels offer limited prognostic utility for individual patients.
- Open Access
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214657
Use of Brain MRI in Cerebral Adrenoleukodystrophy
Background and ObjectivesCerebral adrenoleukodystrophy (CALD) is a common manifestation of adrenoleukodystrophy (ALD) in men. Early detection of CALD lesions through MRI screening is critical to al...
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214657
Open AccessUse of Brain MRI in Cerebral Adrenoleukodystrophy
Background and ObjectivesCerebral adrenoleukodystrophy (CALD) is a common manifestation of adrenoleukodystrophy (ALD) in men. Early detection of CALD lesions through MRI screening is critical to al...
- Open Access
- 5 February 2026
- Published by Elsevier in SSRN Electronic Journal
Real-World Outcomes of Risdiplam in 5q Spinal Muscular Atrophy Over 30 Months in Adolescents and Adults: A Multicentre, Prospective, Observational SMArtCARE Study
Background: Risdiplam is approved for the treatment of 5q-SMA from birth for all types and stages. However, broader data for adults are scarce. We aimed to assess safety and efficacy of risdiplam in adults with SMA.Methods: This is an observational cohort study at 38 academic clinical sites in German-speaking countries. Patients with genetically confirmed 5q-SMA (age 16–69 years) were included and received risdiplam treatment for a minimum treatment time of 6 months to a follow-up of up to 30 months. Primary outcome was the change in the total Revised Upper Limb Module (RULM) score, assessed at baseline to months 4-6, 12-14 and 28-30, and based on pre–post comparisons. This study is registered with the German Clinical Trials Register (DRKS00012699).Findings: Risdiplam showed significant motor improvement across a wide phenotypic spectrum of adult SMA patients regardless of age, SMN2 copy number, and functional status. 74% of patients improved or stabilized at 30 months in RULM; patients do not only deteriorate less rapidly but continue to stabilize or even improve at later time points. Maximum RULM improvement was 1.37 points in SMA3 patients at month 12/14, while at all other timepoints, both in SMA1 and SMA2 patients, mean RULM improvement was below 1 and at all time points below the CMC of 2. We did not detect a correlation between RULM improvement and age, sex or body weight, nor significant changes in HFMSE and 6MWT. No new safety findings were detected.Interpretation: Our study provides real-world data from the multinational SMArtCARE registry on efficacy and safety of risdiplam in 194 adult ambulatory and non-ambulatory SMA patients over 4-30 months of treatment.Funding: Financial support for the SMArtCARE registry is provided by Biogen, Novartis and Roche. Declaration of Interest: BS, BK, CB, CS, CR, EH, GSa, GS, MS, OS and VP declare no conflicts of interest. AB received honoraria for advisory board attendance, speaker’s fees from Biogen, Novartis, Roche, Italpharmaco, SantheraMT received honoraria for advisory board attendance, speaker’s fees and research funding from Alexion, Amicus, AstraZeneca, Sanofi Genzyme, Takeda, outside of the present work. AE received speakers´ fees and honoraria for advisory board attendance from Novartis, Biogen, Roche AH received funding for Travel and/or Speaker Honoraria from Roche, Biogen, Novartis, PTC Therapeutics, Santhera, Biomarin, and Takeda. He received research support from Roche, Sanofi, Takeda, Biomarin. AR received speaker fees from Amylyx Pharmaceuticals, ROCHE, Argenx, UCB Pharma, Alexion Pharma, Zambon and ITF Pharma, travel support for congress from Zambon and Johnson&Johnson and served on advisory boards for Biogen and Argenx, outside of the submitted work. ASN reports Adborad Meetings with Roche, Biogen, Novartis and Santhera Pharmaceuticals. CN received honoraria for advisory board attendance, speaker’s fees and travel grants from Biogen USA, Biogen Switzerland, Roche, Sanofi Genezyme, Mitsubishi Tanabe, Alexion, Argenx, Amicus, Johnson & Johnson, Amgen, Jannsen DH received honoraria for advisory board attendance from Novartis. DZ received honoraria for advisory board attendance from Biogen and Amicus, for consultancy from Novartis, and travel support for conference attendance from Zambon, outside of the present work. FK received speaker honoraria from Roche, Amicus, Alexion, Sanofi; travel support for conference attendance from Roche, ITF Pharma and Amicus, and served on advisory boards for Amicus, Roche, and Abcuro. GMzH received compensation for serving on scientific advisory boards (JnJ, Immunovant), speaker honoraria (Amgen, Argenx) and scientific project funding (Biogen). GW has received honoraria for advisory board attendance, speaker’s fees from Roche, Novartis, Alnylam and AstraZeneca outside of the present work. HC received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, and Roche. HK is serving on a scientific advisory board for Novartis and Scholar Rock and received travel expenses and speaker honoraria from Biogen, Pfizer, Roche, and Sanofi-Aventis. HLo received support for research projects and clinical trials from Amplo Biotechnology, AMO Pharma, argenx, Biogen, Desitin, Fulcrum Therapeutics, Harmony Biosciences, KYE Pharmaceuticals, Milo Biotechnology, Novartis, Pfizer, PTC Therapeutics, Hoffman-La Roche Limited, Sanofi-Genzyme, Santhera, Sarepta, Satellos, Spark Therapeutics and Ultragenyx. HL is the Editor-in-chief for the Journal of Neuromuscular Diseases (IOS Press). JJ received compensation for advisory boards and funding for travel or speaker honoraria from Avexis/Novartis, Biogen, IFT, Roche, PTC, Pfizer, Santhera and Sarepta Therapeutics. JKi received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, ScholarRock and Roche. JK received support to attend scientific conferences or meetings from Roche KV received honoraria for lectures, travel expenses, and/or served as a consultant on advisory boards for Novartis, Roche, Biogen, Santhera, Sanofi, ITF, and Scholar Rock. MA received honoraria fro Roche for advisory board attendance. MB received compensation for advisory board attendance and speaker´s honoraria from Novartis, Biogen, Roche and ITF Pharma. MCW has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, PharNext, PTC Therapeutics, Roche, Santhera, Sarepta, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Biogen, Novartis, PTC Therapeutics, Santhera, and worked as an ad-hoc consultant for Affinia, Audentes Therapeutics, Avexis, Biogen, BridgeBio, Edgewise, Fulcrum, Grünenthal, ML Bio, Novartis, Pfizer, PharNEXT, PTC Therapeutics, Roche. MD has received speaker fees, advisory board and consultant honoraria from Biogen, Hoffmann-La Roche, Sanofi and AstraZeneca, outside of the present work....
- 5 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessReal-World Outcomes of Risdiplam in 5q Spinal Muscular Atrophy Over 30 Months in Adolescents and Adults: A Multicentre, Prospective, Observational SMArtCARE Study
Background: Risdiplam is approved for the treatment of 5q-SMA from birth for all types and stages. However, broader data for adults are scarce. We aimed to assess safety and efficacy of risdiplam in adults with SMA.Methods: This is an observational cohort study at 38 academic clinical sites in German-speaking countries. Patients with genetically confirmed 5q-SMA (age 16–69 years) were included and received risdiplam treatment for a minimum treatment time of 6 months to a follow-up of up to 30 months. Primary outcome was the change in the total Revised Upper Limb Module (RULM) score, assessed at baseline to months 4-6, 12-14 and 28-30, and based on pre–post comparisons. This study is registered with the German Clinical Trials Register (DRKS00012699).Findings: Risdiplam showed significant motor improvement across a wide phenotypic spectrum of adult SMA patients regardless of age, SMN2 copy number, and functional status. 74% of patients improved or stabilized at 30 months in RULM; patients do not only deteriorate less rapidly but continue to stabilize or even improve at later time points. Maximum RULM improvement was 1.37 points in SMA3 patients at month 12/14, while at all other timepoints, both in SMA1 and SMA2 patients, mean RULM improvement was below 1 and at all time points below the CMC of 2. We did not detect a correlation between RULM improvement and age, sex or body weight, nor significant changes in HFMSE and 6MWT. No new safety findings were detected.Interpretation: Our study provides real-world data from the multinational SMArtCARE registry on efficacy and safety of risdiplam in 194 adult ambulatory and non-ambulatory SMA patients over 4-30 months of treatment.Funding: Financial support for the SMArtCARE registry is provided by Biogen, Novartis and Roche. Declaration of Interest: BS, BK, CB, CS, CR, EH, GSa, GS, MS, OS and VP declare no conflicts of interest. AB received honoraria for advisory board attendance, speaker’s fees from Biogen, Novartis, Roche, Italpharmaco, SantheraMT received honoraria for advisory board attendance, speaker’s fees and research funding from Alexion, Amicus, AstraZeneca, Sanofi Genzyme, Takeda, outside of the present work. AE received speakers´ fees and honoraria for advisory board attendance from Novartis, Biogen, Roche AH received funding for Travel and/or Speaker Honoraria from Roche, Biogen, Novartis, PTC Therapeutics, Santhera, Biomarin, and Takeda. He received research support from Roche, Sanofi, Takeda, Biomarin. AR received speaker fees from Amylyx Pharmaceuticals, ROCHE, Argenx, UCB Pharma, Alexion Pharma, Zambon and ITF Pharma, travel support for congress from Zambon and Johnson&Johnson and served on advisory boards for Biogen and Argenx, outside of the submitted work. ASN reports Adborad Meetings with Roche, Biogen, Novartis and Santhera Pharmaceuticals. CN received honoraria for advisory board attendance, speaker’s fees and travel grants from Biogen USA, Biogen Switzerland, Roche, Sanofi Genezyme, Mitsubishi Tanabe, Alexion, Argenx, Amicus, Johnson & Johnson, Amgen, Jannsen DH received honoraria for advisory board attendance from Novartis. DZ received honoraria for advisory board attendance from Biogen and Amicus, for consultancy from Novartis, and travel support for conference attendance from Zambon, outside of the present work. FK received speaker honoraria from Roche, Amicus, Alexion, Sanofi; travel support for conference attendance from Roche, ITF Pharma and Amicus, and served on advisory boards for Amicus, Roche, and Abcuro. GMzH received compensation for serving on scientific advisory boards (JnJ, Immunovant), speaker honoraria (Amgen, Argenx) and scientific project funding (Biogen). GW has received honoraria for advisory board attendance, speaker’s fees from Roche, Novartis, Alnylam and AstraZeneca outside of the present work. HC received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, and Roche. HK is serving on a scientific advisory board for Novartis and Scholar Rock and received travel expenses and speaker honoraria from Biogen, Pfizer, Roche, and Sanofi-Aventis. HLo received support for research projects and clinical trials from Amplo Biotechnology, AMO Pharma, argenx, Biogen, Desitin, Fulcrum Therapeutics, Harmony Biosciences, KYE Pharmaceuticals, Milo Biotechnology, Novartis, Pfizer, PTC Therapeutics, Hoffman-La Roche Limited, Sanofi-Genzyme, Santhera, Sarepta, Satellos, Spark Therapeutics and Ultragenyx. HL is the Editor-in-chief for the Journal of Neuromuscular Diseases (IOS Press). JJ received compensation for advisory boards and funding for travel or speaker honoraria from Avexis/Novartis, Biogen, IFT, Roche, PTC, Pfizer, Santhera and Sarepta Therapeutics. JKi received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, ScholarRock and Roche. JK received support to attend scientific conferences or meetings from Roche KV received honoraria for lectures, travel expenses, and/or served as a consultant on advisory boards for Novartis, Roche, Biogen, Santhera, Sanofi, ITF, and Scholar Rock. MA received honoraria fro Roche for advisory board attendance. MB received compensation for advisory board attendance and speaker´s honoraria from Novartis, Biogen, Roche and ITF Pharma. MCW has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, PharNext, PTC Therapeutics, Roche, Santhera, Sarepta, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Biogen, Novartis, PTC Therapeutics, Santhera, and worked as an ad-hoc consultant for Affinia, Audentes Therapeutics, Avexis, Biogen, BridgeBio, Edgewise, Fulcrum, Grünenthal, ML Bio, Novartis, Pfizer, PharNEXT, PTC Therapeutics, Roche. MD has received speaker fees, advisory board and consultant honoraria from Biogen, Hoffmann-La Roche, Sanofi and AstraZeneca, outside of the present work....
- Open Access
- 29 May 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 57, 72-81
Key lessons from the first international treatment eligibility committee: the case of metachromatic leukodystrophy
- 29 May 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 57, 72-81
Open AccessKey lessons from the first international treatment eligibility committee: the case of metachromatic leukodystrophy
- Open Access
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Improving quality of life in rare diseases using disease-specific, multidisciplinary online interventions on the example of rare X-linked adrenoleukodystrophy: a randomized-controlled trial
Background: People with rare diseases (RDs) often require intensive multidisciplinary care in disease-specific centers of excellence (CoE). However, access is limited for most patients living remotely. X-linked adrenoleukodystrophy (X-ALD) is a genetic RD leading to demyelination of the central and peripheral nervous system. Objectives: This randomized-controlled trial tested the feasibility, acceptance, and effectiveness of a multidisciplinary online intervention provided by a CoE on the quality of life (QoL) and well-being of symptomatic women with X-ALD. Design: Single-center, randomized-controlled clinical trial involving 68 German-speaking women with symptomatic X-ALD. Methods: Participants were randomized into an experimental group (EG, n = 34) receiving 12-month online intervention SMART-ALD and a waiting-list control group (WL-CG, n = 34) receiving 6-month SMART-ALD after a 6-month waiting period. Within SMART-ALD, participants were offered regular web-based neurological, social, psychological, and nutritional counseling and fitness training provided by the Leukodystrophy Outpatient Clinic at Leipzig, Germany. Group, time, and interaction effects on primary (self-reported QoL) and secondary (physical and mental health) outcomes after 6-month SMART-ALD were tested by repeated measures ANOVAs. Results: One WL-CG participant dropped out after the waiting period and was excluded from the final analysis. Significant QoL improvements in the EG versus WL-CG were found on self-reported mental health (mean difference (MD): 5.4, 95% confidence interval (CI) (2.8, 13.6), p = 0.020, η 2 = 0.08) and vitality (MD: 8.8, 95% CI (0.1, 17.4), p = 0.002, η 2 = 0.14). Further significant interaction effects emerged for improved knowledge about nutrition (MD: 0.4, 95% CI (−0.7, 1.4), p = 0.002, η 2 = 0.15), socio-medical benefits (MD: 1.8, 95% CI (0.5, 3.0), p = 0.033, η 2 = 0.07), and intense physical activity (MD: 2.2, 95% CI (−3.9, 8.4), p = 0.024, η 2 = 0.10). Conclusion: The study shows that easily accessible, multidisciplinary online interventions provided by the CoE have the potential to improve the QoL in people with RDs by providing regular access to specialized care. Trial registration: This study was registered on ClinicalTrials.gov ( https://clinicaltrials.gov/study/NCT04687007 ).
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Open AccessImproving quality of life in rare diseases using disease-specific, multidisciplinary online interventions on the example of rare X-linked adrenoleukodystrophy: a randomized-controlled trial
Background: People with rare diseases (RDs) often require intensive multidisciplinary care in disease-specific centers of excellence (CoE). However, access is limited for most patients living remotely. X-linked adrenoleukodystrophy (X-ALD) is a genetic RD leading to demyelination of the central and peripheral nervous system. Objectives: This randomized-controlled trial tested the feasibility, acceptance, and effectiveness of a multidisciplinary online intervention provided by a CoE on the quality of life (QoL) and well-being of symptomatic women with X-ALD. Design: Single-center, randomized-controlled clinical trial involving 68 German-speaking women with symptomatic X-ALD. Methods: Participants were randomized into an experimental group (EG, n = 34) receiving 12-month online intervention SMART-ALD and a waiting-list control group (WL-CG, n = 34) receiving 6-month SMART-ALD after a 6-month waiting period. Within SMART-ALD, participants were offered regular web-based neurological, social, psychological, and nutritional counseling and fitness training provided by the Leukodystrophy Outpatient Clinic at Leipzig, Germany. Group, time, and interaction effects on primary (self-reported QoL) and secondary (physical and mental health) outcomes after 6-month SMART-ALD were tested by repeated measures ANOVAs. Results: One WL-CG participant dropped out after the waiting period and was excluded from the final analysis. Significant QoL improvements in the EG versus WL-CG were found on self-reported mental health (mean difference (MD): 5.4, 95% confidence interval (CI) (2.8, 13.6), p = 0.020, η 2 = 0.08) and vitality (MD: 8.8, 95% CI (0.1, 17.4), p = 0.002, η 2 = 0.14). Further significant interaction effects emerged for improved knowledge about nutrition (MD: 0.4, 95% CI (−0.7, 1.4), p = 0.002, η 2 = 0.15), socio-medical benefits (MD: 1.8, 95% CI (0.5, 3.0), p = 0.033, η 2 = 0.07), and intense physical activity (MD: 2.2, 95% CI (−3.9, 8.4), p = 0.024, η 2 = 0.10). Conclusion: The study shows that easily accessible, multidisciplinary online interventions provided by the CoE have the potential to improve the QoL in people with RDs by providing regular access to specialized care. Trial registration: This study was registered on ClinicalTrials.gov ( https://clinicaltrials.gov/study/NCT04687007 ).
- Open Access
- 28 November 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (1) , 12-15
Gene therapy in advanced metachromatic leukodystrophy: tempering expectations
Recently Zhang et al. ( 2024) published their study entitled “Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: A long-term follow-up pilot study.” The authors present three metachromatic leukodystrophy (MLD) patients treated with gene therapy and claim stabilization or even improvement, despite advanced symptomatic disease stage. The metachromatic leukodystrophy initiative (MLDi) ( Schoenmakers et al., 2022), an international collaborative network and registry for MLD, urges caution in interpreting these results, as the evidence raises several critical concerns. These claims risk fostering false hope among MLD patients and their families, particularly given the significant gaps in the data provided ( Fig. 1).
- 28 November 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (1) , 12-15
Open AccessGene therapy in advanced metachromatic leukodystrophy: tempering expectations
Recently Zhang et al. ( 2024) published their study entitled “Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: A long-term follow-up pilot study.” The authors present three metachromatic leukodystrophy (MLD) patients treated with gene therapy and claim stabilization or even improvement, despite advanced symptomatic disease stage. The metachromatic leukodystrophy initiative (MLDi) ( Schoenmakers et al., 2022), an international collaborative network and registry for MLD, urges caution in interpreting these results, as the evidence raises several critical concerns. These claims risk fostering false hope among MLD patients and their families, particularly given the significant gaps in the data provided ( Fig. 1).
- 15 March 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (10) , 3562-3572
Dominant CST3 variants cause adult onset leukodystrophy without amyloid angiopathy
Leukodystrophies are rare genetic white matter disorders that have been regarded as mainly occurring in childhood. Recent years altered this perception, as a growing number of leukodystrophies was described to have an onset at adult ages. Still, many adult patients presenting with white matter changes remain without a specific molecular diagnosis. We describe a novel adult onset leukodystrophy in 16 patients from eight families carrying one of four different stop-gain or frameshift dominant variants in the CST3 gene. Clinical and radiological features differ markedly from the previously described Icelandic Cerebral Amyloid Angiopathy that was found in patients carrying p.Leu68Asn substitution in CST3. The clinical phenotype consists of recurrent episodes of hemiplegic migraine associated with transient unilateral focal deficits and slowly progressing motor symptoms and cognitive decline in mid–old adult ages. In addition, in some cases acute onset clinical deterioration led to a prolonged episode with reduced consciousness and even early death. Radiologically, pathognomonic changes are found at typical predilection sites involving the deep cerebral white matter sparing a periventricular and directly subcortical rim, the middle blade of corpus callosum, posterior limb of the internal capsule, middle cerebellar peduncles, cerebral peduncles, and specifically the globus pallidus. Histopathologic characterization in two autopsy cases did not reveal angiopathy, but instead micro- to macrocystic degeneration of the white matter. Astrocytes were activated at early stages and later on displayed severe degeneration and loss. In addition, despite loss of myelin, elevated numbers of partly apoptotic oligodendrocytes were observed. A structural comparison of the variants in CST3 suggests that specific truncations of Cystatin C result in an abnormal function, possibly by rendering the protein more prone to aggregation. Future studies are required to confirm the assumed effect on the protein and to determine pathophysiologic downstream events at the cellular level.
- 15 March 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (10) , 3562-3572
Dominant CST3 variants cause adult onset leukodystrophy without amyloid angiopathy
Leukodystrophies are rare genetic white matter disorders that have been regarded as mainly occurring in childhood. Recent years altered this perception, as a growing number of leukodystrophies was described to have an onset at adult ages. Still, many adult patients presenting with white matter changes remain without a specific molecular diagnosis. We describe a novel adult onset leukodystrophy in 16 patients from eight families carrying one of four different stop-gain or frameshift dominant variants in the CST3 gene. Clinical and radiological features differ markedly from the previously described Icelandic Cerebral Amyloid Angiopathy that was found in patients carrying p.Leu68Asn substitution in CST3. The clinical phenotype consists of recurrent episodes of hemiplegic migraine associated with transient unilateral focal deficits and slowly progressing motor symptoms and cognitive decline in mid–old adult ages. In addition, in some cases acute onset clinical deterioration led to a prolonged episode with reduced consciousness and even early death. Radiologically, pathognomonic changes are found at typical predilection sites involving the deep cerebral white matter sparing a periventricular and directly subcortical rim, the middle blade of corpus callosum, posterior limb of the internal capsule, middle cerebellar peduncles, cerebral peduncles, and specifically the globus pallidus. Histopathologic characterization in two autopsy cases did not reveal angiopathy, but instead micro- to macrocystic degeneration of the white matter. Astrocytes were activated at early stages and later on displayed severe degeneration and loss. In addition, despite loss of myelin, elevated numbers of partly apoptotic oligodendrocytes were observed. A structural comparison of the variants in CST3 suggests that specific truncations of Cystatin C result in an abnormal function, possibly by rendering the protein more prone to aggregation. Future studies are required to confirm the assumed effect on the protein and to determine pathophysiologic downstream events at the cellular level.
- Open Access
- 24 May 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1163107
Case report: Treatment of advanced CSF1-receptor associated leukoencephalopathy with hematopoietic stem cell transplant
CSF1 receptor-related leukoencephalopathy is a rare genetic disorder presenting with severe, adult-onset white matter dementia as one of the leading symptoms. Within the central nervous system, the affected CSF1-receptor is expressed exclusively in microglia cells. Growing evidence implicates that replacing the defective microglia with healthy donor cells through hematopoietic stem cell transplant might halt disease progression. Early initiation of that treatment is crucial to limit persistent disability. However, which patients are suitable for this treatment is not clear, and imaging biomarkers that specifically depict lasting structural damage are lacking. In this study, we report on two patients with CSF1R-related leukoencephalopathy in whom allogenic hematopoietic stem cell transplant at advanced disease stages led to clinical stabilization. We compare their disease course with that of two patients admitted in the same timeframe to our hospital, considered too late for treatment, and place our cases in context with the respective literature. We propose that the rate of clinical progression might be a suitable stratification measure for treatment amenability in patients. Furthermore, for the first time we evaluate [18F] florbetaben, a PET tracer known to bind to intact myelin, as a novel MRI-adjunct tool to image white matter damage in CSF1R-related leukoencephalopathy. In conclusion, our data add evidence for allogenic hematopoietic stem cell transplant as a promising treatment in CSF1R-related leukoencephalopathy patients with slow to moderate disease progression.
- 24 May 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1163107
Open AccessCase report: Treatment of advanced CSF1-receptor associated leukoencephalopathy with hematopoietic stem cell transplant
CSF1 receptor-related leukoencephalopathy is a rare genetic disorder presenting with severe, adult-onset white matter dementia as one of the leading symptoms. Within the central nervous system, the affected CSF1-receptor is expressed exclusively in microglia cells. Growing evidence implicates that replacing the defective microglia with healthy donor cells through hematopoietic stem cell transplant might halt disease progression. Early initiation of that treatment is crucial to limit persistent disability. However, which patients are suitable for this treatment is not clear, and imaging biomarkers that specifically depict lasting structural damage are lacking. In this study, we report on two patients with CSF1R-related leukoencephalopathy in whom allogenic hematopoietic stem cell transplant at advanced disease stages led to clinical stabilization. We compare their disease course with that of two patients admitted in the same timeframe to our hospital, considered too late for treatment, and place our cases in context with the respective literature. We propose that the rate of clinical progression might be a suitable stratification measure for treatment amenability in patients. Furthermore, for the first time we evaluate [18F] florbetaben, a PET tracer known to bind to intact myelin, as a novel MRI-adjunct tool to image white matter damage in CSF1R-related leukoencephalopathy. In conclusion, our data add evidence for allogenic hematopoietic stem cell transplant as a promising treatment in CSF1R-related leukoencephalopathy patients with slow to moderate disease progression.